Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News WPD Pharmaceuticals Inc WPDPF


Primary Symbol: C.WBIO

Industrials Technology
WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in... see more

Recent & Breaking News (CSE:WBIO)

WPD Pharmaceuticals Board of Directors Approved the Raise of WPD Poland's Share Capital

Newsfile September 20, 2022

CSE Bulletin: Suspensions (MCCN, MEAL, WBIO, TELE, GBMC, CBDN)

Newsfile July 11, 2022

IIROC Trading Halt - WBIO

Canada NewsWire July 11, 2022

WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences

GlobeNewswire May 16, 2022

WPD Pharmaceuticals Signs Consortium Agreement on EuroNanoMed Project

GlobeNewswire March 7, 2022

WPD Pharmaceuticals (CSE:WBIO) proposes restructuring of Polish subsidiary

Brieanna McCutcheon  February 9, 2022

WPD Pharmaceuticals Announces Proposed Restructuring of Polish Subsidiary

GlobeNewswire February 9, 2022

WPD Pharmaceuticals Announces Appointment of New Director

GlobeNewswire February 3, 2022

WPD Pharmaceuticals (CSE:WBIO) secures sublicense rights for cancer treatment

Caroline Egan  February 1, 2022

WPD Pharmaceuticals Secures Berubicin Sub-License Rights in Perpetuity

GlobeNewswire February 1, 2022

WPD Pharmaceuticals Enters into Amended and Restated Sublicense Agreement with Moleculin Biotech

GlobeNewswire January 25, 2022

WPD Pharmaceuticals Signs Agreement with NCRD for $6.3M Grant for the Development of Liposomal Annamycin, Intended as a Treatment for AML

GlobeNewswire December 16, 2021

WPD Pharmaceuticals Announces AGSM Results

GlobeNewswire October 1, 2021

WPD Pharmaceuticals (CSE:WBIO) schedules AGM for September 29

Brieanna McCutcheon  September 2, 2021

WPD Pharmaceuticals Announces AGM September 29; Plans Different Path to Fundraising Through Delisting; WPD Poland Arranges Additional Loans; Communications Consultant in Poland

GlobeNewswire September 2, 2021

WPD Pharmaceuticals' Licensor Receives FDA Fast Track Designation for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme; WPD Poland Arranges Loans

GlobeNewswire July 12, 2021

WPD Pharmaceuticals Plans to Commence Phase Ib/II Study of Berubicin for the Treatment of Glioblastoma in 2H 2021

GlobeNewswire June 28, 2021

WPD Pharmaceuticals (CSE:WBIO) invited to join international research consortium

Brieanna McCutcheon  June 10, 2021

WPD Pharmaceuticals Invited to Join International Research Consortium

GlobeNewswire June 10, 2021

WPD Pharmaceuticals Provides Update on Audited Financial Statements

GlobeNewswire May 14, 2021